Form 4: MapLight Therapeutics GC Sells Shares for Tax Obligations
Statement of Changes in Beneficial Ownership
General Counsel Kristopher Hanson sold 1,827 shares of MapLight Therapeutics to cover statutory tax withholding obligations.
Summary
- General Counsel Kristopher Hanson sold a total of 1,827 shares of Voting Common Stock on April 15 and April 16, 2026.
- The sales were executed to satisfy statutory tax withholding obligations related to the vesting of restricted stock units.
- The shares were sold at weighted average prices ranging from $26.80 to $27.49 per share.
- Following these transactions, the reporting person retains beneficial ownership of 190,165 shares.
Sentiment
Score: 5
Explanation: StockSavvy.ai views this as a neutral event, as the sale was purely administrative to satisfy tax obligations rather than a discretionary divestment.
Positives
- The sale was non-discretionary, specifically executed to satisfy tax obligations upon the vesting of equity awards.
Negatives
- Reduction in the direct equity stake held by a key member of the executive leadership team.
Risks
- Market volatility could impact the value of remaining equity holdings for insiders.
Future Outlook
No forward-looking guidance or strategic outlook provided in this filing.
Management Comments
- The reporting person undertakes to provide full information regarding the number of shares sold at each separate price within the reported ranges upon request.
Industry Context
StockSavvy.ai notes that mandatory 'sell-to-cover' transactions are standard corporate practice for executives to manage tax liabilities associated with equity compensation and do not typically signal a change in management sentiment regarding company performance.
Comparison to Industry Standards
- The transaction follows standard regulatory compliance procedures for executive equity management in the biotechnology sector.
- The use of weighted average pricing for tax-related sales is consistent with common practices among publicly traded firms.
Stakeholder Impact
- Minimal impact on shareholders as the transaction was a routine tax-related sell-to-cover event.
Next Steps
- No future actions or milestones were disclosed in this filing.
Key Dates
| Date | Description |
|---|---|
| 03/31/2026 | Date of acquisition of 410 shares under the Issuer's stock purchase plan. |
| 04/15/2026 | Date of initial transaction involving the sale of 1,529 shares. |
| 04/16/2026 | Date of subsequent transactions involving the sale of 298 shares. |
| 04/17/2026 | Date of filing of the Form 4. |
Keywords
MapLight Therapeutics, MPLT, Insider Trading, Form 4, Tax Withholding, Equity Vesting
Disclaimer:The information provided here is for general informational purposes only and does not constitute financial advice, recommendation, or endorsement of any kind. It may contain errors or omissions. You should not rely on this information to make financial decisions. Always seek the advice of a qualified financial professional before making any investment or financial decisions. Use of this information is at your own risk.